DelawareHS 1 for HB 332153rd General Assembly (2024–2026)House

AN ACT TO AMEND TITLE 16 OF THE DELAWARE CODE RELATING TO KRATOM.

Sponsored By: Melanie Ross Levin (Democratic)

Signed by Governor

Personalized for You

How does this bill affect your finances?

Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Bill Overview

Analyzed Economic Effects

1 provisions identified: 0 benefits, 0 costs, 1 mixed.

Delaware limits kratom sales and marketing

Delaware's Kratom Consumer Protection Act bans selling, giving, or marketing kratom to anyone under 21. It covers plant materials, extracts, compounds, and synthetic equivalents, including products made to mimic natural kratom alkaloids. Products for human use are covered in any form, including pills, powders, gummies, shots, and drinks. Banned marketing includes cartoons, superheroes, video game references, and images of foods mainly intended for minors. It also includes copied youth-product trademarks, youth-associated symbols or celebrities, and images of people who appear under 27. Claims about intoxication or mental changes that appeal to children are banned. Products cannot be stored or displayed where people under 21 can reach them, unless those people are employees. Violations are class B misdemeanors. An accused person has a defense if the underage person presented photo identification that reasonably made them appear at least 21. By January 1, 2027, the Division of Alcohol & Tobacco Enforcement must report to the Governor and legislature. It must consult Delaware's public health and substance abuse and mental health divisions. The report must assess testing capabilities and recommend retail licensing, compliance checks, enforcement, administrative penalties, product testing, and enforcement funding and staffing. It must also address rules for kratom, synthetic kratom, and concentrated 7-hydroxymitragynine, including limits based on strength and health risks. This reporting requirement does not itself establish retail licenses or product testing requirements.

Sponsors & Cosponsors

Sponsor

  • Melanie Ross Levin

    Democratic • House

Cosponsors

  • Marie Pinkney

    Democratic • Senate

Roll Call Votes

All Roll Calls

Yes: 58 • No: 1

Senate vote • 7/1/2026

Passed (2/3 required)

Yes: 19 • No: 0

House vote • 6/16/2026

Passed (2/3 required)

Yes: 39 • No: 1

Actions Timeline

  1. Signed by Governor

    9/8/2026Governor
  2. Passed By Senate. Votes: 19 YES 2 NOT VOTING

    7/1/2026Senate
  3. Reported Out of Committee (Health & Social Services) in Senate with 1 Favorable, 4 On Its Merits

    6/24/2026Senate
  4. Assigned to Health & Social Services Committee in Senate

    6/16/2026Senate
  5. Passed By House. Votes: 39 YES 1 NO 1 ABSENT

    6/16/2026House
  6. was introduced and adopted in lieu of HB 332

    6/11/2026House

Bill Text

  • Current

    6/11/2026

Related Bills

Back to State Legislation